MRT68921
目录号 : GC14086
An inhibitor of ULK1/2
Cas No.:1190379-70-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 2.9 nM and 1.1 nM for ULK1 and ULK 2, respectively.
MRT68921 is a dual autophagy kinase ULK1/2 inhibitor.
Autophagy is found to be a critical cell-degradative and protective process recycling damaged and long-lived cellular components. ULK1 is a serine/threonine protein kinase that is important for the initial stages of autophagy.
In vitro: MRT68921 was identified to be relatively specific, but still could inhibit a number of kinases by over 80%. Most importantly, TBK1/IKK as well as the AMPK-related kinases were still found to be targeted. Moreover, by using LKB1 knock-out MEFs, it was found that LC3 flux was comparable with matched, wild-type MEFs and could be inhibited to the same extent in the treatment with MRT68921. Thus, these kinases are suggested to be not the target of MRT68921 in blocking autophagy. In addition, MRT68921 was found to be able to block the WT-restored ATG13 phosphorylation and autophagy, which was similar to cells expressing endogenous ULK1. In contrast, in cells expressing a similar level of M92T ULK1, MRT68921 could not reduce either ATG13 phosphorylation or LC3 flux, which indicated that MRT68921 was truly able to block autophagy via ULK1 kinase inhibition [1].
In vivo: So far, there is no animal in vivo data reported.
Clinical trial: Up to now, MRT68921 is still in the preclinical development stage.
Reference:
[1] Petherick KJ, Conway OJ,Mpamhanga C,Osborne SA,Kamal A,Saxty B,Ganley IG. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem.2015 May 1;290(18):11376-83.
Kinase experiment: | Kinase assays are carried out in 50 mM Tris-HCl, pH 7.4, 10 mM magnesium acetate, 0.1 mM EGTA, and 0.1% β-mercaptoethanol, containing 30 μM cold ATP, and 0.5 μCi of [γ-32P]ATP for 5 min at 25 °C. Prior to ATP addition, reaction mixes are pre-warmed to 25 °C for 5 min. Reactions are stopped by the addition of sample buffer, followed by SDS-PAGE, transfer to nitrocellulose, and analysis by autoradiography and immunoblot[1]. |
Cell experiment: | MEFs and 293T cells are grown in DMEM, supplemented with 10% fetal bovine serum and penicillin/streptomycin, and cultured at 37°C, 5% CO2. For induction of autophagy, cells are typically grown to 75% confluency, ished twice, and incubated in Earle's balanced salt solution (EBSS) for 1 h (or complete medium as a control). MRT67307 (10 μM), MRT68921 (1 μM), AZD8055 (1 μM), or bafilomycin A1 (50 nM) is included[1]. |
References: [1]. Petherick KJ, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015 May 1;290(18):11376-83. | |
| Cas No. | 1190379-70-4 | SDF | |
| Canonical SMILES | O=C(C1CCC1)NCCCNC2=NC(NC3=CC4=C(CN(C)CC4)C=C3)=NC=C2C5CC5.[xHCl] | ||
| 分子式 | C25H34N6O·xHCl | 分子量 | 434.58 |
| 溶解度 | ≥ 2.2mg/mL in DMSO with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3011 mL | 11.5054 mL | 23.0107 mL |
| 5 mM | 0.4602 mL | 2.3011 mL | 4.6021 mL |
| 10 mM | 0.2301 mL | 1.1505 mL | 2.3011 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet